Bortezomib: A new therapeutic option for POEMS syndrome

Kaygusuz I., Tezcan H., Cetiner M., Kocakaya O., Uzay A., Bayik M.

European Journal of Haematology, cilt.84, sa.2, ss.175-177, 2010 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 84 Sayı: 2
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1111/j.1600-0609.2009.01341.x
  • Dergi Adı: European Journal of Haematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.175-177
  • Anahtar Kelimeler: Bortezomib, POEMS syndrome, Polyneuropathy
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objective: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. Methods: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib. Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically. Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome. © 2009 John Wiley & Sons A/S.